{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:08:49Z","timestamp":1775480929186,"version":"3.50.1"},"reference-count":14,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2005,5,6]],"date-time":"2005-05-06T00:00:00Z","timestamp":1115337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>To compare the onset and duration of action of the new antihistamine levocetirizine with that of the second\u2010generation antihistamine fexofenadine using the Vienna Challenge Chamber (VCC). The latter is an environment where subjects can be exposed to specific aeroallergens in controlled and reproducible conditions allowing for precise comparisons of anti\u2010allergic drugs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ninety\u2010four subjects received a single dose of levocetirizine 5\u2003mg, fexofenadine 120\u2003mg or placebo in a random order using a three\u2010way cross\u2010over design. On day 1, subjects were exposed to grass pollens (1500 grains\/m<jats:sup>3<\/jats:sup>) in the VCC over a period of 4\u2003h. Treatment was given 2\u2003h after the start of challenge. On day 2, 22\u2003h after drug intake, subjects were again exposed to pollens for 6\u2003h. Specified symptoms were assessed by the subjects every 15\u2003min using 5\u2010point scales. The main efficacy parameter was the change from baseline in the Major Symptom Complex Score (MSCS\u2003=\u2003sum of rhinorrhea, sneezing, itchy nose and eyes).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Baseline characteristics, including symptoms scores, were similar in the three study groups. During the first 2\u2003h after drug intake both antihistamines achieved clinically relevant and significant (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) improvements in symptom scores. Twenty\u2010two to 24\u2003h after drug intake, mean (SEM) MSCS reductions were: 1.9 (0.3) after placebo (baseline of 9.7), 3.8 (0.3) after fexofenadine (baseline of 9.9), and 5.1 (0.3) after levocetirizine (baseline of 9.8). Levocetirizine was significantly (<jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001) more effective than fexofenadine with a score difference of 1.3 (95% CI 0.7, 1.9). This was maintained until the end of the study (up to 28\u2003h).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>A rapid onset of action in alleviating seasonal allergic rhinitis (SAR) symptoms of subjects exposed to grass pollens in the VCC was observed after levocetirizine and fexofenadine. Levocetirizine was more effective than fexofenadine at and later than 22\u2003h after drug intake, an indication of the longer\u2010duration of action of levocetirizine.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2005.02377.x","type":"journal-article","created":{"date-parts":[[2005,6,20]],"date-time":"2005-06-20T12:38:34Z","timestamp":1119271114000},"page":"24-31","source":"Crossref","is-referenced-by-count":37,"title":["Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration"],"prefix":"10.1111","volume":"60","author":[{"given":"Friedrich","family":"Horak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra U.","family":"Zieglmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Zieglmayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kavina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Lemell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,5,6]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.115569"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2003.12.589"},{"key":"e_1_2_6_4_2","first-page":"373","article-title":"The cost of productivity losses associated with allergic rhinitis","volume":"6","author":"Crystal\u2010Peters J","year":"2000","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2003.1550"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s000110300050"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2745.2002.01509.x"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1358\/dot.2001.37.7.844188"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)61995-3"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1368-5031.2004.0117.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(03)01879-7"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000053799"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079904125003700"},{"key":"e_1_2_6_14_2","first-page":"283","article-title":"Levocetirizine but not desloratadine inhibits histamine\u2010induced changes of nasal temperature measured by facial thermography: a pilot study","author":"Larbig M","year":"2003","journal-title":"EAACI 2003 Abstract Book pharma service GmbH"},{"key":"e_1_2_6_15_2","first-page":"80","article-title":"Twenty\u2010four hour anti\u2010H1 activity of levocetirizine measured by thermography is superior to fexofenadine","author":"Larbig M","year":"2004","journal-title":"EAACI 2004 Abstract Book pharma service documediaS GmbH"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2005.02377.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2005.02377.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:15:47Z","timestamp":1697393747000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2005.02377.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5,6]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1365-2125.2005.02377.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02377.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5,6]]}}}